Adimmune Corp Total Liabilities
Adimmune Corp total liabilities. Based on the latest financial reports, Adimmune Corp (4142) has total liabilities worth NT$3.53 Billion TWD (≈ $111.13 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Adimmune Corp liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Adimmune Corp (2007–2024)
Total liabilities of Adimmune Corp from 2007 to 2024. This chart illustrates how Adimmune Corp's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Adimmune Corp to see how much of total assets are deployed in long-term investments.
Adimmune Corp Competitors by Total Liabilities
The table below lists competitors of Adimmune Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Caxton
JSE:CAT
|
South Africa | ZAC1.84 Billion |
|
SIGA Technologies Inc
NASDAQ:SIGA
|
USA | $67.77 Trillion |
|
Natures Sunshine Products Inc
NASDAQ:NATR
|
USA | $90.51 Million |
|
TrueCar Inc
NASDAQ:TRUE
|
USA | $34.51 Million |
|
Best SA
WAR:BST
|
Poland | zł1.71 Billion |
|
Thye Ming Industrial Co Ltd
TW:9927
|
Taiwan | NT$1.13 Billion |
|
Coastal Contracts Bhd
KLSE:5071
|
Malaysia | RM62.42 Million |
|
X3 Acquisition Corp. Ltd. Class A Ordinary Shares
NASDAQ:XCBE
|
USA | $5.85 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Adimmune Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Adimmune Corp asset portfolio.
Liquidity & Leverage Metrics
Adimmune Corp Total Liabilities Ratios Explained
Adimmune Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Adimmune Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Adimmune Corp (2007–2024)
The table below shows the annual total liabilities of Adimmune Corp from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$2.92 Billion ≈ $91.99 Million |
-21.23% |
| 2023-12-31 | NT$3.71 Billion ≈ $116.79 Million |
+42.37% |
| 2022-12-31 | NT$2.60 Billion ≈ $82.03 Million |
+65.05% |
| 2021-12-31 | NT$1.58 Billion ≈ $49.70 Million |
-14.48% |
| 2020-12-31 | NT$1.84 Billion ≈ $58.12 Million |
-32.79% |
| 2019-12-31 | NT$2.74 Billion ≈ $86.47 Million |
-28.19% |
| 2018-12-31 | NT$3.82 Billion ≈ $120.41 Million |
+12.53% |
| 2017-12-31 | NT$3.40 Billion ≈ $107.01 Million |
-7.95% |
| 2016-12-31 | NT$3.69 Billion ≈ $116.25 Million |
+110.90% |
| 2015-12-31 | NT$1.75 Billion ≈ $55.12 Million |
+25.90% |
| 2014-12-31 | NT$1.39 Billion ≈ $43.78 Million |
-38.22% |
| 2013-12-31 | NT$2.25 Billion ≈ $70.87 Million |
-0.05% |
| 2012-12-31 | NT$2.25 Billion ≈ $70.91 Million |
+11.97% |
| 2011-12-31 | NT$2.01 Billion ≈ $63.33 Million |
+48.38% |
| 2010-12-31 | NT$1.35 Billion ≈ $42.68 Million |
-30.24% |
| 2009-12-31 | NT$1.94 Billion ≈ $61.18 Million |
+89.58% |
| 2008-12-31 | NT$1.02 Billion ≈ $32.27 Million |
+367.95% |
| 2007-12-31 | NT$218.90 Million ≈ $6.90 Million |
-- |
About Adimmune Corp
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops Adim… Read more